Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6052W HIGH $10.99
Volume
870.98 K
Value Traded
3.57 M
Short % Float
42.33%
-25.21%Week
-64.5%1 Month
-94.2%3 Month
-92.5%6 Month
-94.31%5 Year
-96.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
13.61 M
EPS (TTM)
-9.91
P/E Ratio
-
Ent. Value
-51.50 M
Total Shares
22.68 M
Float Shares
18.58 M
Insiders
18.07%
Institutions
86.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KPTI Catalyst Timeline
Dated clinical, regulatory and corporate events for Karyopharm Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Karyopharm Therapeutics Inc.
1337Total events
5Upcoming
293Tier-1 (high impact)
2012 to 2026Coverage
Upcoming catalysts 2
Event history 50
●sNDA SubmissionXPOVIOApprovedRegulatory Filing
sNDA submitted to FDA for XPOVIO plus ruxolitinib in myelofibrosis
myelofibrosissource ↗
◆Late-BreakerSelinexorApprovedPresentation
Late-breaking abstract accepted for oral presentation at EHA 2026
myelofibrosissource ↗
◆Oral PresentationSelinexorApprovedPresentation
Oral presentation of Phase 3 SENTRY trial results at EHA 2026
myelofibrosissource ↗
◆Oral PresentationPresentation
Virtual fireside chat hosted by Cantor featuring Karyopharm management and KOL discussing XPORT-EC-042 trial
◆Oral PresentationPresentation
Karyopharm to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
◆Quarterly UpdateCorporate
Investor conference call featuring expert perspectives on Phase 3 SENTRY trial
◆PublicationSelinexorApprovedPresentation
Simultaneous publication of SENTRY results in Journal of Clinical Oncology
myelofibrosissource ↗
◆Late-BreakerSelinexorApprovedPresentation
Late-breaking oral presentation of Phase 3 SENTRY trial results at ASCO 2026
myelofibrosissource ↗
◆Oral PresentationSelinexorApprovedPresentation
Oral presentation at ASCO 2026 Hematologic Malignancies session
myelofibrosissource ↗
◆Oral PresentationSelinexorApprovedPresentation
Oral presentation of Phase 3 SENTRY trial results at 2026 ASCO Annual Meeting
myelofibrosissource ↗
◆Topline ReadoutSelinexorApprovedClinical Data
Top-line data from Phase 3 XPORT-EC-042 trial expected mid-2026
endometrial cancersource ↗
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference Fireside Chat
▲Enrollment CompleteSelinexorApprovedTrial
Completed enrollment of Phase 3 XPORT-EC-042 trial in endometrial cancer
endometrial cancersource ↗
◆Topline ReadoutSelinexorApprovedClinical Data
Top-line data from Phase 3 XPORT-EC-042 trial in endometrial cancer expected in mid-2026
endometrial cancersource ↗
◆Topline ReadoutSelinexorApprovedClinical Data
Phase 3 SENTRY trial met first co-primary endpoint of SVR35, missed second co-primary endpoint of Abs-TSS
myelofibrosissource ↗
◆Oral PresentationSelinexorApprovedPresentation
Conference call to discuss SENTRY results
myelofibrosissource ↗
▲Primary Endpoint MetSelinexorApprovedClinical Data
SENTRY met first co-primary endpoint of SVR35 at week 24
myelofibrosissource ↗
▼Primary Endpoint MissedSelinexorApprovedClinical Data
SENTRY did not meet second co-primary endpoint of Abs-TSS
myelofibrosissource ↗
◆Topline ReadoutSelinexorApprovedClinical Data
Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026
myelofibrosissource ↗
●Quarterly UpdateCorporate
Conference call to discuss Q4 2025 financial results and 2026 outlook
◆Topline ReadoutSelinexorApprovedClinical Data
Expected top-line data read-out from Phase 3 XPORT-EC-042 trial
TP53 wild-type endometrial cancersource ↗
▲Topline ReadoutXPOVIOApprovedClinical Data
Topline results of Phase 3 SENTRY trial
myelofibrosissource ↗
▲Oral PresentationXPOVIOApprovedPresentation
SENTRY results presented at ASCO 2026
myelofibrosissource ↗
▲PublicationXPOVIOApprovedPresentation
SENTRY results published in Journal of Clinical Oncology
myelofibrosissource ↗
●Quarterly UpdateCorporate
Preliminary unaudited full year 2025 total revenue ~$145M and U.S. XPOVIO net product revenue ~$115M
◆Oral PresentationPresentation
Karyopharm to participate in Baird's Biotech Discovery Series fireside chat
◆Oral PresentationPresentation
Karyopharm management to participate in fireside chat at Piper Sandler 37th Annual Healthcare Conference
●Oral PresentationSelinexorApprovedPresentation
Presented preliminary baseline characteristics and blinded aggregate safety data from SENTRY at ASH 2025
myelofibrosissource ↗
▼Equity OfferingCorporate
Private placement of common stock and warrants for ~$8.75M gross proceeds
▲Enrollment CompleteSelinexorApprovedTrial
Enrollment completed in Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis
myelofibrosissource ↗
●Quarterly UpdateXPOVIOApprovedCorporate
Preliminary Q3 2025 total revenue and XPOVIO net product revenue guidance
◆Topline ReadoutSelinexorApprovedClinical Data
Top-line results from pivotal Phase 3 trial of selinexor + ruxolitinib in treatment-naïve MF
treatment-naïve myelofibrosissource ↗
▲Enrollment CompleteSelinexorApprovedTrial
Phase 3 SENTRY trial enrollment completed
myelofibrosissource ↗
◆Quarterly UpdateXPOVIOApprovedCorporate
Preliminary Q3 2025 total revenue $42-44M, XPOVIO net product revenue ~$32M
oncologysource ↗
▲Enrollment CompleteSelinexorApprovedTrial
Completed enrollment in Phase 3 SENTRY trial of selinexor plus ruxolitinib in JAKi-naïve myelofibrosis
myelofibrosissource ↗
▲Enrollment CompleteSelinexorApprovedTrial
Completed enrollment of Phase 3 SENTRY trial with 353 patients
myelofibrosissource ↗
◆Enrollment CompleteSelinexorApprovedTrial
New patient screening for Phase 3 SENTRY trial expected to close this week
myelofibrosissource ↗
◆Enrollment CompleteSelinexorApprovedTrial
Full enrollment of Phase 3 SENTRY trial expected in August 2025
myelofibrosissource ↗
◆Topline ReadoutSelinexorApprovedClinical Data
Top-line data from Phase 3 SENTRY trial
myelofibrosis (JAKi-naïve)source ↗
Past FDA Catalysts and PDUFA Decisions
How KPTI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-31 | selinexor in combination with ruxolitinib | sNDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$11M
Pipeline Value
$147M
Commercial Value
Undervalued
Valuation Signal
5
Drugs Scored
2.1x
rNPV / MCap
Top 24%
Micro Cap(rank 159 of 658)
Percentile Rank
Karyopharm Therapeutics Inc. carries a moderate pipeline score (47/100), with $1.2B risk-adjusted pipeline value, led by KPT-8602 in Relapsed/Refractory Multiple Myeloma (RRMM) (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $146.6M x 1.0 = $147M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| XPOVIO | $124M | $110M | +13.3% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KPT-8602 Small moleculeCompletedNCT02649790 | Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1 | COMPLETED | 277 | Dec 23, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every KPTI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| selinexor Fast TrackOrphan | myelofibrosis | Phase 3 | 2026-06-02 | near doubling of patients achieving spleen volume reduction at week 24; >50% reduction of risk of death versus Ruxolitinib; more patients achieving ≥20% reductions in VAF as early as week 24Read More | Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical OncologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Abate KristinOfficer (Chief Accounting Officer) | Sell | -378 23,404 held | $1.19 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KPTI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.2 % (100 %) | 18.73 M | 1.92 M |
KPTI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KPTI ranks across every disease it competes in
Competitive Position is a premium feature
See how KPTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKPTI News
KPTI▼ -7.5%on this news· ran to -26% by day 3
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics has granted 333 restricted stock units (RSUs) to a newly-hired employee as part of its 2022 Inducement Stock Incentive Plan. This award, effective from September 30, 2026, will vest over three years, contingent upon the employee's continued service. The move aligns with Nasdaq Listing Rule 5635(c)(4) and highlights Karyopharm's efforts to attract talent in the competitive biopharma sector.
Read more →KPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics has granted 1,850 restricted stock units to two new employees as part of its 2022 Inducement Stock Incentive Plan. These awards are intended to incentivize the new hires under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on continued employment.
Read more →KPTI▲ +10.2%on this news
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Therapeutics has submitted a supplemental New Drug Application to the FDA for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis patients. The application seeks Accelerated Approval and includes data from the Phase 3 SENTRY trial, which showed promising results. The company has requested Priority Review, potentially shortening the review timeline to six months.
Read more →KPTIKaryopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Karyopharm Therapeutics reported its second quarter 2026 financial results, highlighting a planned sNDA submission for selinexor in combination with ruxolitinib for myelofibrosis. The company aims for this to be the first approved combination therapy for the condition. Despite a revenue decrease compared to last year, Karyopharm's net product revenue showed growth, and they reaffirmed their full-year revenue guidance.
Read more →KPTI▼ -7.5%on this news
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
Karyopharm Therapeutics Inc. will report its second quarter 2026 financial results on August 13, 2026. A conference call will be held at 8:00 a.m. ET to discuss these results and other updates. The company is known for its innovative cancer therapies, particularly XPOVIO, which is approved in multiple countries.
Read more →KPTIKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
Karyopharm Therapeutics announced topline results from its Phase 3 XPORT-EC-042 trial, which evaluated selinexor in endometrial cancer. Although the trial did not meet its primary endpoint of progression-free survival, a trend favoring selinexor was noted. The safety profile remained consistent with previous data, and the company plans to continue monitoring patients for longer-term outcomes.
Read more →KPTIKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Karyopharm Therapeutics plans to submit a supplemental New Drug Application (sNDA) for selinexor combined with ruxolitinib for myelofibrosis in August 2026. This submission follows positive feedback from the FDA regarding the use of spleen volume reduction as a surrogate endpoint. The ongoing Phase 3 SENTRY trial is expected to provide long-term overall survival data to support the application. If approved, this combination therapy could be a significant advancement in treating myelofibrosis.
Read more →KPTIKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Karyopharm Therapeutics Inc. will participate in a virtual fireside chat on June 8, 2026, featuring Dr. Robert Coleman, a leading expert in gynecologic oncology. The event will discuss the company's advancements in cancer therapies, particularly in endometrial cancer. A replay will be available on their website after the event.
Read more →KPTIKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm Therapeutics announced that its late-breaking abstract from the Phase 3 SENTRY trial has been selected for an oral presentation at the 2026 EHA Congress. The trial evaluates the combination of selinexor and ruxolitinib in myelofibrosis patients, showing promising results in spleen volume reduction and overall survival predictions. The findings highlight the potential of selinexor to enhance treatment outcomes beyond traditional JAK inhibitors.
Read more →KPTIKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
Karyopharm Therapeutics announced positive results from its Phase 3 SENTRY trial, demonstrating that the combination of selinexor and ruxolitinib significantly improved patient outcomes in myelofibrosis. The trial showed a near doubling of patients achieving spleen volume reduction at week 24 and a promising overall survival signal. The results were presented at the ASCO 2026 Annual Meeting and published in the Journal of Clinical Oncology.
Read more →KPTI▲ +7.9%on this newsshared move
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
Karyopharm Therapeutics will host an investor conference call on June 2, 2026, featuring Dr. John Mascarenhas, who will discuss the Phase 3 SENTRY trial results. This follows his presentation at the 2026 ASCO Annual Meeting. The call aims to provide insights into the combination therapy of selinexor and ruxolitinib for myelofibrosis.
Read more →KPTIKaryopharm to Participate at the 2026 Jefferies Global Healthcare Conference
Karyopharm Therapeutics Inc. will participate in the 2026 Jefferies Global Healthcare Conference with a fireside chat scheduled for June 4, 2026. The event will feature the company's senior management discussing their innovative cancer therapies, including XPOVIO. A live webcast will be available for those unable to attend in person.
Read more →KPTIKaryopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Karyopharm Therapeutics Inc. reported its first quarter financial results for 2026, highlighting total revenue of $35.1 million, primarily driven by net product revenue of $29.2 million from XPOVIO. The company announced the completion of enrollment for its Phase 3 XPORT-EC-042 trial in endometrial cancer and the acceptance of SENTRY trial results for a late-breaking presentation at the upcoming ASCO meeting. Despite some challenges such as decreased demand and unmet trial endpoints, Karyopharm maintains an optimistic outlook with several important data readouts expected in mid-2026.
Read more →KPTIKaryopharm to Participate at Upcoming Investor Conferences
Karyopharm Therapeutics Inc. announced participation in two upcoming investor conferences in May 2026. The events include fireside chats at the H.C. Wainwright 4th Annual BioConnect Investor Conference and the RBC 2026 Global Healthcare Conference. Live webcasts will be available on the company's website, highlighting its commitment to cancer therapy innovation.
Read more →KPTIKaryopharm to Report First Quarter 2026 Financial Results on May 14, 2026
Karyopharm Therapeutics Inc. will report its first quarter 2026 financial results on May 14, 2026. The management team will host a conference call at 8:00 a.m. ET to discuss the results and provide company updates. Interested parties can access the call via phone or through a live audio webcast.
Read more →KPTIKaryopharm
Karyopharm Therapeutics Inc. announced that their late-breaking abstract was accepted for oral presentation at the 2026 ASCO Annual Meeting. The presentation will showcase results from the Phase 3 SENTRY trial, focusing on the efficacy of selinexor combined with ruxolitinib in myelofibrosis patients. The event is scheduled for June 2, 2026, and reflects Karyopharm's continued commitment to developing innovative cancer therapies. Presenting findings from the trial, which has important implications for myelofibrosis treatment, signifies a vital step in advancing cancer care.
Read more →KPTI▼ -18.3%on this news
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Karyopharm Therapeutics announced that its Phase 3 SENTRY trial met its first co-primary endpoint, showing significant improvement in spleen volume reduction for patients with myelofibrosis treated with selinexor and ruxolitinib. Although the trial did not meet its second endpoint regarding symptom improvement, it indicated a promising signal for overall survival. The company plans to discuss these results with the FDA and potentially file a supplemental new drug application.
Read more →About Karyopharm Therapeutics Inc.
Headquarters85 WELLS AVENUE, NEWTON, MA, 02459
BIOPHARMAWATCH ELITE PLUS
Trade the next KPTI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime